<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662138</url>
  </required_header>
  <id_info>
    <org_study_id>0304769</org_study_id>
    <nct_id>NCT04662138</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse</brief_title>
  <official_title>Safety and Efficacy of Directly Acting Antiviral Agents in Genotype 4 Hepatitis C Virus Relapse Among Egyptian Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of hepatitis C virus (HCV) Direct Acting Antivirals (DAAs) is to achieve&#xD;
      undetectable HCV RNA in the blood. A response that should be maintained for at least 12 weeks&#xD;
      from completion of therapy. This is called sustained virological response (SVR) which&#xD;
      corresponds to cure of HCV infection as risk of later relapse is very small. SVR is important&#xD;
      to achieve improvement in liver necroinflammation and fibrosis and to decrease complications&#xD;
      of cirrhosis.&#xD;
&#xD;
      Failing to achieve SVR after treatment requires another regimen for these experienced&#xD;
      patients.&#xD;
&#xD;
      Real-world data are always needed to evaluate and improve our practices. Here investigators&#xD;
      aim to assess tolerability and efficacy of different regimens used for management of genotype&#xD;
      4 HCV relapse.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2020</start_date>
  <completion_date type="Anticipated">May 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response</measure>
    <time_frame>12 weeks after completion of treatment</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Relapse</condition>
  <condition>Antivirals</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>directly acting antivirals</intervention_name>
    <description>Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with HCV relapse after sofosbuvir plus either NS5A or protease inhibitor who&#xD;
        will start another HCV treatment at Alexandria University Viral Hepatitis Treatment Unit or&#xD;
        Alexandria University Liver Clinics in the period from 24/8/2020 to 23/8/2021.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all patients with HCV relapse after sofosbuvir plus either Non-structural protein 5 A&#xD;
             (NS5A) or protease inhibitor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Kamal</last_name>
    <phone>01279734654</phone>
    <email>Ahmed.Kamal@alexmed.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alexandria University.</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Kamal</last_name>
      <phone>01279734654</phone>
      <email>Ahmed.Kamal@alexmed.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

